Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.25 USD

1.25
2,386,975

+0.02 (1.21%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $1.24 -0.01 (-0.80%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

by Zacks Equity Research

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

by Zacks Equity Research

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

by Zacks Equity Research

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for OPKO Health (OPK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 0.71% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.

Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.

OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

by Zacks Equity Research

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.

Best Momentum Stocks to Buy for July 19th

by Zacks Equity Research

NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.

New Strong Buy Stocks for July 19th

by Zacks Equity Research

SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.

Best Momentum Stocks to Buy for July 12th

by Zacks Equity Research

RMTI, ZUO and OPK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2023.

Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

by Zacks Equity Research

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug

by Zacks Equity Research

The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.